JOP20250189A1 - تركيبة قابلة للحقن ومستحضر صيدلاني يحتوي عليها وطريقة تحضيرها - Google Patents

تركيبة قابلة للحقن ومستحضر صيدلاني يحتوي عليها وطريقة تحضيرها

Info

Publication number
JOP20250189A1
JOP20250189A1 JOJO/P/2025/0189A JOP20250189A JOP20250189A1 JO P20250189 A1 JOP20250189 A1 JO P20250189A1 JO P20250189 A JOP20250189 A JO P20250189A JO P20250189 A1 JOP20250189 A1 JO P20250189A1
Authority
JO
Jordan
Prior art keywords
injectable formulation
preparation
pharmaceutical preparation
preparation containing
pharmaceutical
Prior art date
Application number
JOJO/P/2025/0189A
Other languages
Arabic (ar)
English (en)
Inventor
Aeri Kim
John Kim
Jungmin Yun
Original Assignee
Onconic Therapeutics Inc
Jeil Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onconic Therapeutics Inc, Jeil Pharmaceutical Co Ltd filed Critical Onconic Therapeutics Inc
Publication of JOP20250189A1 publication Critical patent/JOP20250189A1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JOJO/P/2025/0189A 2023-02-01 2025-07-28 تركيبة قابلة للحقن ومستحضر صيدلاني يحتوي عليها وطريقة تحضيرها JOP20250189A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20230013947 2023-02-01
PCT/IB2024/050869 WO2024161316A1 (en) 2023-02-01 2024-01-31 Injectable composition, pharmaceutical formulation including the same, and method for preparing the composition

Publications (1)

Publication Number Publication Date
JOP20250189A1 true JOP20250189A1 (ar) 2025-07-28

Family

ID=92024104

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2025/0189A JOP20250189A1 (ar) 2023-02-01 2025-07-28 تركيبة قابلة للحقن ومستحضر صيدلاني يحتوي عليها وطريقة تحضيرها

Country Status (15)

Country Link
EP (1) EP4658244A1 (https=)
JP (1) JP2026505092A (https=)
KR (1) KR20240121186A (https=)
CN (1) CN118415999A (https=)
AR (1) AR131668A1 (https=)
AU (1) AU2024215883A1 (https=)
CL (1) CL2025002270A1 (https=)
CO (1) CO2025011347A2 (https=)
DO (1) DOP2025000185A (https=)
IL (1) IL322431A (https=)
JO (1) JOP20250189A1 (https=)
MX (1) MX2025008735A (https=)
PE (1) PE20252396A1 (https=)
TW (1) TW202432120A (https=)
WO (1) WO2024161316A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120827558A (zh) * 2024-04-19 2025-10-24 丽珠医药集团股份有限公司 咪唑并[1,2-a]吡啶衍生物药物组合物及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1682133A1 (en) * 2003-11-03 2006-07-26 AstraZeneca AB Imidazo 1,2-a pyridine derivatives for the treatment of silent gastro-esophageal reflux
AR051041A1 (es) * 2004-10-04 2006-12-13 Altana Pharma Ag Bencimidazoles triciclicos condensados
FI20086158A0 (fi) * 2008-12-03 2008-12-03 Mikael Dahlstroem Imidatsopyridiinijohdannaiset
GB0906470D0 (en) * 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
KR101777971B1 (ko) * 2016-07-05 2017-09-12 제일약품주식회사 이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이의 용도

Also Published As

Publication number Publication date
AR131668A1 (es) 2025-04-16
CO2025011347A2 (es) 2025-09-18
IL322431A (en) 2025-09-01
KR20240121186A (ko) 2024-08-08
AU2024215883A1 (en) 2025-07-31
JP2026505092A (ja) 2026-02-10
CN118415999A (zh) 2024-08-02
MX2025008735A (es) 2025-11-03
DOP2025000185A (es) 2026-02-15
EP4658244A1 (en) 2025-12-10
CL2025002270A1 (es) 2025-10-03
TW202432120A (zh) 2024-08-16
PE20252396A1 (es) 2025-10-10
WO2024161316A1 (en) 2024-08-08

Similar Documents

Publication Publication Date Title
JOP20250189A1 (ar) تركيبة قابلة للحقن ومستحضر صيدلاني يحتوي عليها وطريقة تحضيرها
CY1115526T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει πιμοβενδανη
CY1124917T1 (el) Παρασκευη στερεων συμπλοκων κυκλοδεξtρινης για παραδοση οφθαλμικου δραστικου φαρμακευτικου συστατικου
BR112021021857A2 (pt) Métodos para formação de complexos de inclusão com derivados de beta-ciclodextrina hidrofílicos e composições dos mesmos
ATE297433T1 (de) Filmbildende zusammensetzungen aus pullulan
AR082049A1 (es) Formulaciones liquidas de rupatadina fumarato
MA59082B1 (fr) Formulations à concentration élevée d'anticorps dirigés contre les protofibrilles de peptide bêta-amyloïde et leurs méthodes d'utilisation
WO2020025742A9 (en) Immediate release formulation of a triple combination of active pharmaceutical ingredients useful in the treatment of polycystic ovary syndrome
SA522431528B1 (ar) نواتج تجفيد/محاليل من بوليميكسين و زيدوفودين
MX2025006915A (es) Preparación farmacéutica de un compuesto de imidazolinona, método de preparación y uso de esta
MX2021002611A (es) Composición farmacéutica que comprende complejos de ciclodextrina de anetol tritiona o derivados del mismo.
CL2023001215A1 (es) Formulación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso de preparación
WO2019097413A1 (en) Stable non-aqueous pharmaceutical compositions
EA201650048A1 (ru) Способ получения конъюгата гиалуронидазы с производными полиэтиленпиперазина и применение полученного конъюгата
MX2024003230A (es) Composiciones de tiostrepton y preparacion de estas.
WO2021216450A8 (en) Opioid antagonist formulations
KR20130030606A (ko) 코르티코스테로이드, 항히스타민제 및 β-사이클로덱스트린을 포함하는, 안정성이 개선된 약학 조성물
JOP20240282A1 (ar) صيغة أوكسيتوسين
JP5849550B2 (ja) ステロイド性抗炎症薬含有外用剤
ATE486599T1 (de) Pharmazeutische zusammensetzung mit amlodipinbesilat und lisinoprildihydrat und herstellungsverfahren dafür
WO2021245700A3 (en) Pharmaceutical lipid compositions of remdesivir
CR20220620A (es) Composición farmacéutica acuosa de levilimab y su uso
JOP20250188A1 (ar) مستحضر صيدلاني وطريقة تحضيره وتركيبة الأقراص
FI20030426A0 (fi) Syklodekstriinikompleksit
TW202617132A (zh) 低溶解度化合物的緩釋劑型及其緩釋劑型的製備方法